## CLAIMS

1. A pharmaceutical composition comprising at least an anti-MSRV/HERV-W Env ligand and at least one Nitric Oxyde radical inhibitory drug.

2. The pharmaceutical composition of claim 1, wherein said anti-HERV-W Env ligand is selected among a scFV, a Fab fragment or an antibody, more particularly a chimeric, engineered or humanized antibody, and particularly an IgG, such as an IgG1 or an IgG4.

3. The pharmaceutical composition of claim 1 or 2, wherein said anti-HERV-W Env ligand comprises each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.

4. The pharmaceutical composition of any one of claims 1 to 3, wherein said Nitric Oxyde radical inhibitory drug is chosen among $N^g$-nitro-L-arginine-methylester (L-NAME), S-methyl-isothiourea (SMT), fumaric acid or dimethyl fumarate (DMF).

5. The pharmaceutical composition of any one of claim 1 to 4 for use in for the prevention and/or the treatment of the remyelination blockage in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

6. The pharmaceutical composition of any one of claims 1 to 4 for use for the prevention and/or the treatment of the remyelination blockage in Multiple Sclerosis (MS) more particularly of Remitting-Relapsing Multiple Sclerosis (RRMS), the progressive Multiple Sclerosis such as Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive Multiple Sclerosis (PPMS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), psychoses such as Schizophrenia or bipolar Disorder and other demyelinating diseases associated with expression of HERV-W Envelope protein (Env), in particular of its MSRV subtype.

## CLAIMS

1. A pharmaceutical composition comprising at least an anti-MSRV/HERV-W Env ligand and at least one Nitric Oxide radical inhibitory drug,
wherein said Nitric Oxide radical inhibitory drug is chosen among $N^g$-nitro-L-arginine-methylester (L-NAME), S-methyl-isothiourea (SMT), fumaric acid or dimethyl fumarate (DMF).

2. The pharmaceutical composition of claim 1, wherein said anti-HERV-W Env ligand is selected among a scFV, a Fab fragment or an antibody, more particularly a chimeric, engineered or humanized antibody, and particularly an IgG, such as an IgG1 or an IgG4.

3. The pharmaceutical composition of claim 1 or 2, wherein said anti-HERV-W Env ligand comprises each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6.

4. Use of the pharmaceutical composition of any one of claims 1 to 3 for the manufacture of a medicament for the prevention and/or the treatment of the remyelination blockage in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype,
wherein said disease associated with the expression of HERV-W envelope protein is selected from the group consisting of Multiple Sclerosis (MS), the Remitting-Relapsing Multiple Sclerosis (RRMS), the progressive Multiple Sclerosis such as Secondary Progressive Multiple Sclerosis (SPMS) or Primary Progressive Multiple Sclerosis (PPMS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), psychoses such as Schizophrenia or bipolar Disorder.